| We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 6 February 2020, highlighting Roche data on risdiplam in type 2/3 spinal muscular atrophy from the SUNFISH Part 2 trial presented at the 2nd International Scientific Congress on spinal muscular atrophy, (5 - 7 Feb) in Evry, France. Agenda:
Please dial in as outlined below: 15:00 – 15:45 CET / 14:00 - 14:45 GMT 09:00 – 09:45 am EST / 06:00 - 06:45 am PST Audio webcast and conference call will start with presentations followed by a Q&A session (live access to the speakers). Access to Audio webcast Please access by clicking on > ir.roche.com Access to Conference Call (pre-registration required) You will receive phone numbers, passcode and your personal PIN to direct access the conference call by pre-registering here. Should you have any issues with the registration, please dial the following numbers on the day of the conference call 10-15 minutes prior to conference start: +41 (0) 58 310 50 00 (Europe & RoW) +44 (0) 207 107 0613 (UK) +1 631 570 56 13 (USA) A replay of the webcast will be available via > ir.roche.com |
| Best regards, Karl Mahler Head of Investor Relations and Roche Group Planning | Sabine Borngräber Investor Relations Officer |
| Roche Investor Relations | |
| Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com | Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
| Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com | Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
| Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com | Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
| Investor Relations North America | |
| Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com | Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com |
get the latest news and updates to your inbox.